Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Study Limitations First, the absence of patient-level data precluded a more detailed investigation of covariates potentially influencing treatment effects and introduce some heterogeneity in patient population and endpoint definitions across trials
Safety and Efficacy: Proven Results GLP-1 agonists like Semaglutide and Tirzepatide have demonstrated significant effectiveness in weight loss when used as prescribed
Several drugs are in advanced clinical trials: In Phase III trials: IBI362 (Innovent/Eli Lilly), CagriSema (Novo Nordisk), Retatrutide (Eli Lilly), and Survodutide (Boehringer Ingelheim)
Oral semaglutide drops and sublingual semaglutide offer needle-free options for patients who prefer non-injectable formats
Many patients have tried other weight loss programs with little progress, which makes them unsure whether a new program will deliver real results
After the initial treatment phase, your doctor may recommend transitioning off the medication once your health goals are achieved
